Communiqués Tempus AI, Inc.

Actions

TEM

US88023B1035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 05/10/2026			Varia. 5j.	Varia. 1 janv.
83,55 ^USD	+9,03 %		-1,80 %	+41,49 %

28/09	Tempus AI, Inc. obtient l’autorisation de la FDA pour Tempus ECG-MR, son produit d’intelligence artificielle conçu pour identifier les cas non diagnostiqués d’insuffisance mitrale	CI
28/09	Tempus AI obtient l’autorisation de la FDA pour son outil ECG-MR destiné à identifier les régurgitations mitrales modérées ou sévères	MT

Communiqués

01/10	Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026	BU
28/09	Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation	BU
21/09	Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model	BU
11/09	Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation	BU
09/09	Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology	BU
04/09	Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference	BU
24/08	Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs	BU
04/08	Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications	BU
30/07	Tempus: Q2 Earnings Snapshot	AQ
30/07	Tempus Reports Second Quarter 2026 Results	BU
22/07	Tempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision Medicine	BU
20/07	Tempus AI : Acquisition of PSNL Investor Deck	PU
20/07	Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform	BU
16/07	Tempus Highlights Landmark Publication Demonstrating Safe, Real-World Deployment of Paige Prostate AI Suite in the UK National Health Service	BU
09/07	Tempus to Report Second Quarter 2026 Financial Results on July 30	BU
25/06	Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers	BU
11/06	Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm	BU
10/06	Genetics in Medicine Study Demonstrates How Ambry Genetics ExomeReveal RNA Testing Can Improve Diagnostic Clarity in Exome Testing	AQ
09/06	Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing	BU
05/06	Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference	BU
03/06	Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members	BU
01/06	Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH	BU
31/05	Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development	BU
30/05	Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community	BU
30/05	Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results	BU